Prostatype Genomics AB (publ) (STO:PROGEN)

Market Cap	69.13M +60.9%
Revenue (ttm)	805.00K +144.7%
Net Income	-37.90M
EPS	-0.69
Shares Out	691.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,710,108
Open	0.1035
Previous Close	0.1040
Day's Range	0.0938 - 0.1050
52-Week Range	0.0788 - 2.2800
Beta	1.42
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 11, 2027

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 200...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROGEN

Financial Performance

In 2025, Prostatype Genomics AB's revenue was 594,000, an increase of 198.49% compared to the previous year's 199,000. Losses were -44.50 million, 8.41% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 19, 2026

Data Sources Report a data error